Up to $1 billion will be available to boost African vaccine manufacturing as part of a new scheme set up by Gavi, the Vaccine Alliance, the global health organization said on Thursday.
Elagolix sodium, an oral short-acting nonpeptide gonadotropin-releasing hormone antagonist has been approved by the FDA at a dose of 300 mg twice daily with add-back therapy for up to 24 months.
Though many people remain on the fence about getting the latest COVID vaccine booster, new research suggests a strong argument for getting the shot this winter.